Hemagglutinin-specific T cell receptor (HA-TCR)

The Hemagglutinin-specific T cell receptor (TCR), exemplified by the well-characterized HA1.7 clone, is a heterodimeric antigen receptor found on CD4+ T helper cells that specifically recognizes peptides derived from the influenza virus hemagglutinin (HA) protein (Hennecke & Wiley, 2002). It primarily targets the immunodominant HA 306-318 epitope when presented by Major Histocompatibility Complex (MHC) class II molecules, such as HLA-DR1 and HLA-DR4, on the surface of antigen-presenting cells (Lamb et al., 1995). Upon binding to the peptide-MHC complex, the TCR initiates a signaling cascade that activates the T cell, leading to the production of cytokines like interferon-gamma and the orchestration of an adaptive immune response against influenza infection (Fossum et al., 2013). This TCR system is also a critical model for studying molecular mimicry in autoimmune diseases; for instance, HA-specific T cells can cross-react with self-peptides like type II collagen, potentially driving the pathogenesis of rheumatoid arthritis (Li et al., 2006). Therapeutic strategies involving this target include the use of altered peptide ligands (APLs) to modulate or inhibit T cell activation in autoimmunity and the development of TCR-engineered T cell (TCR-T) therapies for infectious diseases. Additionally, next-generation vaccines utilize this pathway by targeting HA antigens directly to MHC class II molecules to enhance T cell priming and protective immunity.

Other names

HA1.7 T cell receptorInfluenza hemagglutinin-specific TCRHA-specific TCRTCR HA1.7Hemagglutinin-specific T-cell receptor

The receptor recognizes the HA 306-318 peptide epitope presented by MHC class II molecules (such as HLA-DR1 or HLA-DR4), triggering a signaling cascade through the CD3 complex that leads to CD4+ T cell activation and cytokine release.